This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Integra LifeSciences Holdings Corporation [IART], a world leader in medical technology, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion,
Peter J. Arduini, President and CEO of Integra, Linda Brown, Sandy Agrella, and Christopher Rull, PAREXEL International Business Development Representatives; and Lionel Leventhal, CBTF Board Treasurer, will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd& Broadway – Broadcast Studio
Wednesday, August 21, 2013– 3:45 p.m. to 4:00 p.m. ET
Contact: Ericia Antoine Children's Brain Tumor Foundation 212-448-9494
email@example.comNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Integra LifeSciences Holdings Corporation [IART]:
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit
PAREXEL International is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through their development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercial services.